What is HC Wainwright’s Forecast for ETON FY2027 Earnings?

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Analysts at HC Wainwright boosted their FY2027 EPS estimates for shares of Eton Pharmaceuticals in a research note issued to investors on Monday, January 6th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of $1.27 per share for the year, up from their prior forecast of $1.25. HC Wainwright has a “Buy” rating and a $17.00 price objective on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.17) per share. HC Wainwright also issued estimates for Eton Pharmaceuticals’ FY2028 earnings at $1.62 EPS and FY2029 earnings at $2.31 EPS.

Separately, Craig Hallum lifted their price target on Eton Pharmaceuticals from $15.00 to $18.00 and gave the stock a “buy” rating in a research report on Wednesday.

Eton Pharmaceuticals Stock Performance

NASDAQ ETON opened at $12.01 on Wednesday. The stock has a 50-day simple moving average of $11.57 and a 200 day simple moving average of $7.32. Eton Pharmaceuticals has a twelve month low of $3.03 and a twelve month high of $15.00. The stock has a market capitalization of $312.87 million, a PE ratio of -54.59 and a beta of 1.38.

Hedge Funds Weigh In On Eton Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in ETON. Westside Investment Management Inc. raised its stake in shares of Eton Pharmaceuticals by 5.7% in the 3rd quarter. Westside Investment Management Inc. now owns 618,675 shares of the company’s stock valued at $3,711,000 after buying an additional 33,275 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Eton Pharmaceuticals by 13.5% in the 3rd quarter. Geode Capital Management LLC now owns 272,696 shares of the company’s stock valued at $1,637,000 after purchasing an additional 32,365 shares during the period. Jane Street Group LLC bought a new stake in shares of Eton Pharmaceuticals in the 3rd quarter valued at approximately $90,000. Parkman Healthcare Partners LLC raised its holdings in shares of Eton Pharmaceuticals by 2.8% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 260,226 shares of the company’s stock worth $1,561,000 after buying an additional 7,029 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Eton Pharmaceuticals during the 3rd quarter worth approximately $54,000. 27.86% of the stock is currently owned by institutional investors.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.